All News
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.
Read Article
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.
Read Article
#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone?
Seems fishy….
oops - #fish #oil #omega3 #fatty #acids do work!
not sure re the huge benefit of ‘immunebiotics’
#EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY
Janet Pope Janetbirdope ( View Tweet)
Closing the care divide in #JIA treatment plenary session
Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1
Biologics have changed the game!
@RheumNow https://t.co/qDqbz8JApe
Bella Mehta bella_mehta ( View Tweet)
Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed:
> Female pts
> Peripheral SpA symptoms
< HLAB27 positive
< Education level
< Objective signs: MRI-inflammation in the spine or elevated CRP levels.
also PROs were worse in
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed:
-SJC = good specificity. Correlated with US synovitis but not patient-defined response
-New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis?
🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro
#EULAR2025
OP0090
@RheumNow
#Strategy https://t.co/W8fuzSgxbJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks
207 pts SON 120 MDA 51% vs. 45% ADA
Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55%
Composite ACR70/PASI100 SON 120 48% vs. 19% ADA
No new safety signal
Ph 3 on the way 2 doses SON 60 &120
#OP0096 https://t.co/w5QtpKbi1W
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE
@RheumNow #EULAR2025 #OP0008
Mrinalini Dey DrMiniDey ( View Tweet)
Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study
•ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002
•PASI75: 40.9% vs 15.4%, p<0.0001
•MDA: 25.6% vs 14.7%, p=0.0007
•FACIT-F: +2.5 vs +1.8
•SAE: 1.9% (low)
TYK2 inhibition shows https://t.co/JXTZRk2itA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy https://t.co/24e7wUV2FB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1:
-CKD progression
-Mortality
-MI
Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007)
#EULAR2025 @RheumNow
Abstract#OP0069 https://t.co/jWI6tvri8O
Jiha Lee JihaRheum ( View Tweet)
Can RA be intercepted?
In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles.
Abstract#OP0004
@RheumNow #EULAR2025 https://t.co/N7YwtYod8w
Jiha Lee JihaRheum ( View Tweet)
Repurposing drugs to #osteoarthritis
No jewel in the rough!
Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs
Not sure this is the way forward for #OA drug discovery 💡
#EULAR2025 @RheumNow @eular_org
Abst#POS565 https://t.co/A6SdXtOo7v
Janet Pope Janetbirdope ( View Tweet)
RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances.
@RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw
Mrinalini Dey DrMiniDey ( View Tweet)
GI symptoms in axSpA
-Cohort of 370 pts with axSpAfrom New Zealand
-Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity
-Bowel symptoms associated with reduced quality of life.
-Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi
Links:
Adela Castro AdelaCastro222 ( View Tweet)
IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1
David Liew drdavidliew ( View Tweet)
MONITOR PsA 200+ pts secondary care "real-life" cohort
65 treated w/ combi csDMARDs
48weeks outcome and 96 weeks
49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD
‼️reasons for discontinuation was AEs in 60% cases not inefficacy
Caveat: analysis not adjusted for https://t.co/L8EczgZTpP
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care.
@RheumNow #EULAR2025 #OP0007
Mrinalini Dey DrMiniDey ( View Tweet)
